Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
G2 Bio Companies
Philadelphia, Pennsylvania, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
G2 Bio Companies were launched in 2021 with a US$200 million commitment from Temasek to fund and develop next‑generation gene therapy and other genetic-based therapeutic candidates emerging from the University of Pennsylvania Gene Therapy Program; public information describes a discovery and translational portfolio but does not yet report any clinical trial results, indicating pre‑clinical stage development[1][2][5].
- Therapeutic areas
- OtherRare DiseasesInfectious Diseases
- Modalities
- Gene therapyGene editingmRNA-based drugs
- Industry
- Biotech
02
Partnerships
University of Pennsylvania Gene Therapy Program[1][5]Temasek[1][2][5]
Beyond the preview
Go deeper on G2 Bio Companies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on G2 Bio Companies.